Pharmacokinetic and pharmacodynamic considerations in the treatment of the elderly patient with hypertension

References

• Lacruz ME, Kluttig A, Hartwig S, et al. Prevalence and incidence of hypertension in the general adult population: results of the CARLA-cohort study. Medicine (Baltimore). 2015;94(22):e952.
   Google Scholar
• Lloyd-Jones DM, Evans JC, Levy D. Hypertension in adults across the age spectrum: current outcomes and control in the community. Jama. 2005;294(4):466–472.
   Google Scholar
• Denardo SJ, Gong Y, Nichols WW, et al. Blood pressure and outcomes in very old hypertensive coronary artery disease patients: an INVEST substudy. Am J Med. 2010;123(8):719–726.
   Google Scholar
• United Nations. Profiles of ageing 2015 (world); 2015.
   Google Scholar
• Rapsomaniki E, Timmis A, George J, et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people. Lancet. 2014;383(9932):1899–1911.
   Google Scholar
• Lee PY, Alexander KP, Hammill BG, et al. Representation of elderly persons and women in published randomized trials of acute coronary syndromes. JAMA. 2001;286(6):708–713.
   Google Scholar
• Shenoy P, Harugeri A. Elderly patients’ participation in clinical trials. Perspect Clin Res. 2015;6(4):184–189.
   Google Scholar
• Messerli FH, Mancia G, Conti CR, et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med. 2006;144(12):884–893.
   Google Scholar
• The SPRINT Research group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103–2116.
   Google Scholar
• Williamson JD, Supiano MA, Applegate WB, et al. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged >/=75 years: a randomized clinical trial. JAMA. 2016;315(24):2673–2682.
   Google Scholar
• Crooks J, O’Malley K, Stevenson IH. Pharmacokinetics in the elderly. Clin Pharmacokinet. 1976;1(4):280–296.
   Google Scholar
• Turnheim K. When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly. Exp Gerontol. 2003;38(8):843–853.
   Google Scholar
• Salwe KJ, Kalyansundaram D, Bahurupi Y. A study on polypharmacy and potential drug-drug interactions among elderly patients admitted in department of medicine of a tertiary care hospital in puducherry. J Clin Diagn Res. 2016;10(2):FC06–FC10.
   Google Scholar
• Passarelli MC, Jacob-Filho W, Figueras A. Adverse drug reactions in an elderly hospitalised population: inappropriate prescription is a leading cause. Drugs Aging. 2005;22(9):767–777.
   Google Scholar
• Rosenthal T, Nussinovitch N. Managing hypertension in the elderly in light of the changes during aging. Blood Press. 2008;17(4):186–194.
   Google Scholar
• Ruzicka M, McCormick B, Magner P, et al. Thiazide diuretic-caused hyponatremia in the elderly hypertensive: will a bottle of nepro a day keep hyponatremia and the doctor away? Study protocol for a proof-of-concept feasibility trial. Pilot Feasibility Stud. 2018;4:71.
   Google Scholar
• Wang G, Fang J, Ayala C. Hypertension-associated hospitalizations and costs in the United States, 1979–2006. Blood Press. 2014;23(2):126–133.
   Google Scholar
• Leendertse AJ, Egberts AC, Stoker LJ, et al. Frequency of and risk factors for preventable medication-related hospital admissions in the Netherlands. Arch Intern Med. 2008;168(17):1890–1896.
   Google Scholar
• Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887–1898.
   Google Scholar
• George J, Bleasdale S, Singleton SJ. Causes and prognosis of delirium in elderly patients admitted to a district general hospital. Age Ageing. 1997;26(6):423–427.
   Google Scholar
• Bulpitt CJ, Fletcher AE, Amery A, et al. The HYpertension in the Very Elderly Trial (HYVET). J Hum Hypertens. 1994;8(8):631–632.
   Google Scholar
• Omboni S, Malacco E, Mallion JM, et al. Olmesartan vs. ramipril in elderly hypertensive patients: review of data from two published randomized, double-blind studies. High Blood Press Cardiovasc Prev. 2014;21(1):1–19.
   Google Scholar
• Cohen JS. Adverse drug effects, compliance, and initial doses of antihypertensive drugs recommended by the joint national committee vs the physicians’ desk reference. Arch Intern Med. 2001;161(6):880–885.
   Google Scholar
• Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. Hypertension. 2018;71(6):1269–1324.
   Google Scholar
• Williams B, Mancia G, Spiering W, et al. ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;ehy339–ehy339.
   Google Scholar
• Abramov D, Cheng H. Controversy in treating the oldest old with hypertension: is the Hypertension in the Very Elderly Trial the final answer? J Am Geriatr Soc. 2009;57(3):570–571.
   Google Scholar
• Kaiser EA, Lotze U, Schäfer HH. Increasing complexity: which drug class to choose for treatment of hypertension in the elderly? Clin Interv Aging. 2014;9:459–475.
   Google Scholar
• Shi S, Klotz U. Age-related changes in pharmacokinetics. Curr Drug Metab. 2011;12(7):601–610.
   Google Scholar
• Duracovic ZV. Pharmacodynamics and pharmacokinetics in the elderly. Period Biol. 2013;115(4):517–520.
   Google Scholar
• Gabardi S, Tullius SG, Krenzien F. Understanding alterations in drug handling with aging: a focus on the pharmacokinetics of maintenance immunosuppressants in the elderly. Curr Opin Organ Transplant. 2015;20(4):424–430.
   Google Scholar
• Wooten JM. Pharmacotherapy considerations in elderly adults. South Med J. 2012;105(8):437–445.
   Google Scholar
• Brenner SS, Klotz U. P-glycoprotein function in the elderly. Eur J Clin Pharmacol. 2004;60(2):97–102.
   Google Scholar
• Fulop T Jr., Worum I, Csongor J, et al. Body composition in elderly people. I. Determination of body composition by multiisotope method and the elimination kinetics of these isotopes in healthy elderly subjects. Gerontology. 1985;31(1):6–14.
   Google Scholar
• Mangoni AA, Jackson SHD. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57(1):6–14.
   Google Scholar
• Kruse WH. Problems and pitfalls in the use of benzodiazepines in the elderly. Drug Saf. 1990;5(5):328–344.
   Google Scholar
• Vinkers CH, Tijdink JK, Luykx JJ, et al. [Choosing the correct benzodiazepine: mechanism of action and pharmacokinetics] Kiezen voor de juiste benzodiazepine: werkingsmechanisme en farmacokinetiek. Ned Tijdschr Geneeskd. 2012;155(35):A4900.
   Google Scholar
• Jain R, Chung SM, Jain L, et al. Implications of obesity for drug therapy: limitations and challenges. Clin Pharmacol Ther. 2011;90(1):77–89.
   Google Scholar
• Wallace SM, Verbeeck RK. Plasma protein binding of drugs in the elderly. Clin Pharmacokinet. 1987;12(1):41–72.
   Google Scholar
• Song JC, White CM. Pharmacologic, pharmacokinetic, and therapeutic differences among angiotensin II receptor antagonists. Pharmacotherapy. 2000;20(2):130–139.
   Google Scholar
• Schmucker DL. Liver function and phase I drug metabolism in the elderly: a paradox. Drugs Aging. 2001;18(11):837–851.
   Google Scholar
• Jacobson PA, Schladt D, Oetting WS, et al. Lower calcineurin inhibitor doses in older compared to younger kidney transplant recipients yield similar troughs. Am J Transplant. 2012;12(12):3326–3336.
   Google Scholar
• Wauthier V, Verbeeck RK, Calderon PB. The effect of ageing on cytochrome p450 enzymes: consequences for drug biotransformation in the elderly. Curr Med Chem. 2007;14(7):745–757.
   Google Scholar
• Zoli M, Magalotti D, Bianchi G, et al. Total and functional hepatic blood flow decrease in parallel with ageing. Age Ageing. 1999;28(1):29–33.
   Google Scholar
• Denic A, Glassock RJ, Rule AD. Structural and functional changes with the aging kidney. Adv Chronic Kidney Dis. 2016;23(1):19–28.
   Google Scholar
• Jani B, Rajkumar C. Ageing and vascular ageing. Postgrad Med J. 2006;82(968):357–362.
   Google Scholar
• Liamis G, Milionis HJ, Elisaf M. A review of drug-induced hypernatraemia. NDT Plus. 2009;2(5):339–346.
   Google Scholar
• Miller M. Fluid and electrolyte homeostasis in the elderly: physiological changes of ageing and clinical consequences. Baillieres Clin Endocrinol Metab. 1997;11(2):367–387.
   Google Scholar
• Schlanger LE, Bailey JL, Sands JM. Electrolytes in the aging. Adv Chronic Kidney Dis. 2010;17(4):308–319.
   Google Scholar
• Conti S, Cassis P, Benigni A. Aging and the renin-angiotensin system. Hypertension. 2012;60(4):878–883.
   Google Scholar
• Belmin J, Levy BI, Michel JB. Changes in the renin-angiotensin-aldosterone axis in later life. Drugs Aging. 1994;5(5):391–400.
   Google Scholar
• Harvey A, Montezano AC, Touyz RM. Vascular biology of ageing—implications in hypertension. J Mol Cell Cardiol. 2015;83:112–121.
   Google Scholar
• Turgut F, Balogun RA, Abdel-Rahman EM. Renin-angiotensin-aldosterone system blockade effects on the kidney in the elderly: benefits and limitations. Clin J Am Soc Nephrol. 2010;5(7):1330–1339.
   Google Scholar
• Nanba K, Vaidya A, Rainey WE. Aging and adrenal aldosterone production. Hypertension. 2018;71(2):218–223.
   Google Scholar
• National Institute for Health and Care Excellence. Hypertension in adults: diagnosis and management; 2011. p. 25.
   Google Scholar
• Tregaskis BF, McDevitt DG. Beta-adrenoceptor-blocking drugs in the elderly. J Cardiovasc Pharmacol. 1990;16(Suppl 5):S25–28.
   Google Scholar
• Ferrara N, Komici K, Corbi G, et al. β-adrenergic receptor responsiveness in aging heart and clinical implications. Front Physiol. 2013;4:396.
   Google Scholar
• Clegg A, Young J, Iliffe S, et al. Frailty in elderly people. Lancet. 2013;381(9868):752–762.
   Google Scholar
• Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56(3):M146–156.
   Google Scholar
• Rockwood K, Song X, MacKnight C, et al. A global clinical measure of fitness and frailty in elderly people. Cmaj. 2005;173(5):489–495.
   Google Scholar
• Li G, Thabane L, Ioannidis G, et al. Comparison between frailty index of deficit accumulation and phenotypic model to predict risk of falls: data from the Global Longitudinal Study of Osteoporosis in Women (GLOW) Hamilton cohort. PLoS ONE. 2015;10(3):e0120144.
   Google Scholar
• Cullinan S, O’Mahony D, O’Sullivan D, et al. Use of a frailty index to identify potentially inappropriate prescribing and adverse drug reaction risks in older patients. Age Ageing. 2016;45(1):115–120.
   Google Scholar
• Cahir C, Bennett K, Teljeur C, et al. Potentially inappropriate prescribing and adverse health outcomes in community dwelling older patients. Br J Clin Pharmacol. 2014;77(1):201–210.
   Google Scholar
• Lau DT, Kasper JD, Potter DE, et al. Hospitalization and death associated with potentially inappropriate medication prescriptions among elderly nursing home residents. Arch Intern Med. 2005;165(1):68–74.
   Google Scholar
• Warwick J, Falaschetti E, Rockwood K, et al. No evidence that frailty modifies the positive impact of antihypertensive treatment in very elderly people: an investigation of the impact of frailty upon treatment effect in the HYpertension in the very elderly trial (HYVET) study, a double-blind, placebo-controlled study of antihypertensives in people with hypertension aged 80 and over. BMC Med. 2015;13:78.
   Google Scholar
• Peel NM. Epidemiology of falls in older age. Can J Aging. 2011;30(1):7–19.
   Google Scholar
• WHO Organization. WHO guidelines on integrated care for older people (ICOPE); 2017. Available from: http://www.who.int/ageing/publications/guidelines-icope/en/
   Google Scholar
• Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 2011;21(2):69–72.
   Google Scholar
• Mader SL, Josephson KR, Rubenstein LZ. Low prevalence of postural hypotension among community-dwelling elderly. Jama. 1987;258(11):1511–1514.
   Google Scholar
• Raiha I, Luutonen S, Piha J, et al. Prevalence, predisposing factors, and prognostic importance of postural hypotension. Arch Intern Med. 1995;155(9):930–935.
   Google Scholar
• Ricci F, Fedorowski A, Radico F, et al. Cardiovascular morbidity and mortality related to orthostatic hypotension: a meta-analysis of prospective observational studies. Eur Heart J. 2015;36(25):1609–1617.
   Google Scholar
• Verwoert GC, Mattace-Raso FU, Hofman A, et al. Orthostatic hypotension and risk of cardiovascular disease in elderly people: the Rotterdam study. J Am Geriatr Soc. 2008;56(10):1816–1820.
   Google Scholar
• Wu JS, Yang YC, Lu FH, et al. Population-based study on the prevalence and correlates of orthostatic hypotension/hypertension and orthostatic dizziness. Hypertens Res. 2008;31(5):897–904.
   Google Scholar
• Alli C, Avanzini F, Bettelli G, et al. Prevalence and variability of orthostatic hypotension in the elderly. Results of the ‘Italian study on blood pressure in the elderly (SPAA)’. The ‘Gruppo Di Studio Sulla Pressione Arteriosa nell’Anziano’. Eur Heart J. 1992;13(2):178–182.
   Google Scholar
• Ang HT, Lim KK, Kwan YH, et al. A systematic review and meta-analyses of the association between anti-hypertensive classes and the risk of falls among older adults. Drugs Aging. 2018;35(7):625–635.
   Google Scholar
• Gupta V, Lipsitz LA. Orthostatic hypotension in the elderly: diagnosis and treatment. Am J Med. 2007;120(10):841–847.
   Google Scholar
• Valbusa F, Labat C, Salvi P, et al. Orthostatic hypotension in very old individuals living in nursing homes: the PARTAGE study. J Hypertens. 2012;30(1):53–60.
   Google Scholar
• Noh J, Kim HC, Shin A, et al. Prevalence of comorbidity among people with hypertension: the Korea national health and nutrition examination survey 2007-2013. Korean Circ J. 2016;46(5):672–680.
   Google Scholar
• Salive ME. Multimorbidity in older adults. Epidemiol Rev. 2013;35(1):75–83.
   Google Scholar
• Anari R, Amani R, Latifi SM, et al. Association of obesity with hypertension and dyslipidemia in type 2 diabetes mellitus subjects. Diabetes Metab Syndr. 2017;11(1):37–41.
   Google Scholar
• Frigerio M, Roubina E. Drugs for left ventricular remodeling in heart failure. Am J Cardiol. 2005;96(12A):10L–18L.
   Google Scholar
• Qato DM, Alexander GC, Conti RM, et al. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA. 2008;300(24):2867–2878.
   Google Scholar
• Giovannini S, van der Roest HG, Carfi A, et al. Polypharmacy in home care in Europe: cross-sectional data from the IBenC study. Drugs Aging. 2018;35(2):145–152.
   Google Scholar
• Jokanovic N, Tan EC, Dooley MJ, et al. Prevalence and factors associated with polypharmacy in long-term care facilities: a systematic review. J Am Med Dir Assoc. 2015;16(6):535e531–512.
   Google Scholar
• Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014;13(1):57–65.
   Google Scholar
• Gandhi S, Fleet JL, Bailey DG, et al. Calcium-channel blocker-clarithromycin drug interactions and acute kidney injury. Jama. 2013;310(23):2544–2553.
   Google Scholar
• Aubert CE, Streit S, Da Costa BR, et al. Polypharmacy and specific comorbidities in university primary care settings. Eur J Intern Med. 2016;35:35–42.
   Google Scholar
• Mazzaglia G, Ambrosioni E, Alacqua M, et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation. 2009;120(16):1598–1605.
   Google Scholar
• Anderson RT, Ory M, Cohen S, et al. Issues of aging and adherence to health interventions. Control Clin Trials. 2000;21(5 Suppl):171S–183S.
   Google Scholar
• Mallion JM, Baguet JP, Siche JP, et al. Compliance, electronic monitoring and antihypertensive drugs. J Hypertens Suppl. 1998;16(1):S75–79.
   Google Scholar
• Weintraub M. Intelligent noncompliance with special emphasis on the elderly. Contemp Pharm Pract. 1981;4(1):8–11.
   Google Scholar
• Hughes CM. Medication non-adherence in the elderly. Drugs Aging. 2004;21(12):793–811.
   Google Scholar
• Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417–2428.
   Google Scholar
• Caballero-Gonzalez FJ. Calcium channel blockers in the management of hypertension in the elderly. Cardiovasc Hematol Agents Med Chem. 2015;12(3):160–165.
   Google Scholar
• Peters R, Booth A, Peters J. A systematic review of calcium channel blocker use and cognitive decline/dementia in the elderly. J Hypertens. 2014;32(10):1945–1957. discussion 1957–1948.
   Google Scholar
• Sica DA, Gehr TW. Calcium-channel blockers and end-stage renal disease: pharmacokinetic and pharmacodynamic considerations. Curr Opin Nephrol Hypertens. 2003;12(2):123–131.
   Google Scholar
• Sarganas G, Knopf H, Grams D, et al. Trends in antihypertensive medication use and blood pressure control among adults with hypertension in Germany. Am J Hypertens. 2016;29(1):104–113.
   Google Scholar
• Bucci C, Mamdani MM, Juurlink DN, et al. Dihydropyridine calcium channel blockers and cardiovascular outcomes in elderly patients: a population-based study. Can J Cardiol. 2008;24(8):629–632.
   Google Scholar
• Abernethy DR, Gutkowska J, Winterbottom LM. Effects of amlodipine, a long-acting dihydropyridine calcium antagonist in aging hypertension: pharmacodynamics in relation to disposition. Clin Pharmacol Ther. 1990;48(1):76–86.
   Google Scholar
• Hunt CM, Westerkam WR, Stave GM. Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol. 1992;44(2):275–283.
   Google Scholar
• Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev. 2009;41(2):67–76.
   Google Scholar
• FDC Pharma. SmPC amlodipine 5mg tablets; 2011 Feb 24. Available from: https://www.medicines.org.uk/emc/product/4036/smpc
   Google Scholar
• Elliott HL, Meredith PA. The clinical consequences of the absorption, distribution, metabolism and excretion of amlodipine. Postgrad Med J. 1991;67(Suppl 3):S20–23.
   Google Scholar
• Wade JR, Sambol NC. Felodipine population dose-response and concentration-response relationships in patients with essential hypertension. Clin Pharmacol Ther. 1995;57(5):569–581.
   Google Scholar
• Mion D Jr., Ortega KC, Gomes MA, et al. Amlodipine 2.5 mg once daily in older hypertensives: a Brazilian multi-centre study. Blood Press Monit. 2004;9(2):83–89.
   Google Scholar
• van Ree JW, van der Pol GA. Low dosages of felodipine ER once daily as monotherapy in elderly hypertensive patients: effect on ambulatory blood pressure and quality of life. J Hum Hypertens. 1996 Sep;10(9):613–618.
   Google Scholar
• Pareek A, Basavanagowdappa H, Zawar S, et al. A randomized, comparative study evaluating the efficacy and tolerability of losartan-low dose chlorthalidone (6.25 mg) combination with losartan-hydrochlorothiazide (12.5 mg) combination in Indian patients with mild-to-moderate essential hypertension. Expert Opin Pharmacother. 2009 Jul;10(10):1529–1536.
   Google Scholar
• Duprez DA, Weintraub HS, Cushman WC, et al. Effect of valsartan, hydrochlorothiazide, and their combination on 24-h ambulatory blood pressure response in elderly patients with systolic hypertension: a ValVET substudy. Blood Press Monit. 2011;16(4):186–196.
   Google Scholar
• Eugene AR. Gender based dosing of metoprolol in the elderly using population pharmacokinetic modeling and simulations. Ijcpt. 2016;5(3):209–215.
   Google Scholar
• Baxter AJ, Spensley A, Hildreth A, et al. β blockers in older persons with heart failure: tolerability and impact on quality of life. Heart. 2002;88(6):611–614.
   Google Scholar
• Hayashi K, Miyagawa K, Sato K, et al. Temocapril, an angiotensin converting enzyme inhibitor, ameliorates age-related increase in carotid arterial stiffness in normotensive subjects. Cardiology. 2006;106(3):190–194.
   Google Scholar
• Ungvari Z, Kaley G, de Cabo R, et al. Mechanisms of vascular aging: new perspectives. J Gerontol A. 2010;65A(10):1028–1041.
   Google Scholar
• Hockings N, Ajayi AA, Reid JL. Age and the pharmacokinetics of angiotensin converting enzyme inhibitors enalapril and enalaprilat. Br J Clin Pharmacol. 1986;21(4):341–348.
   Google Scholar
• Hubbard RE, O’Mahony MS, Calver BL, et al. Plasma esterases and inflammation in ageing and frailty. Eur J Clin Pharmacol. 2008;64(9):895–900.
   Google Scholar
• Soysal P, Stubbs B, Lucato P, et al. Inflammation and frailty in the elderly: A systematic review and meta-analysis. Ageing Res Rev. 2016;31:1–8.
   Google Scholar
• Lees KR, Hughes DM, McNeill CA, et al. Pharmacokinetics of perindopril: therapeutic consequences [Conference Paper]. Clin Exp Hypertens A. 1989;11(SUPPL. 2):499–506.
   Google Scholar
• Kaiser G, Ackermann R, Dieterle W, et al. Pharmacokinetics and pharmacodynamics of the ace inhibitor benazepril hydrochloride in the elderly. Eur J Clin Pharmacol. 1990;38(4):379–385.
   Google Scholar
• Thomson AH, Kelly JG, Whiting B. Lisinopril population pharmacokinetics in elderly and renal disease patients with hypertension. Br J Clin Pharmacol. 1989;27(1):57–65.
   Google Scholar
• Puchler K, Sierakowski B, Roots I. Single dose and steady state pharmacokinetics of temocapril and temocaprilat in young and elderly hypertensive patients. Br J Clin Pharmacol. 1998;46(4):363–367.
   Google Scholar
• Lees KR, Green ST, Reid JL. Influence of age on the pharmacokinetics and pharmacodynamics of perindopril. Clin Pharmacol Ther. 1988;44(4):418–425.
   Google Scholar
• Taddei S. RAS inhibitors’ dose-dependent efficacy: myth or reality? Curr Med Res Opin. 2015;31(7):1245–1256.
   Google Scholar
• Burnier M, Biollaz J. Pharmacokinetic optimisation of angiotensin converting enzyme (ACE) inhibitor therapy. Clin Pharmacokinet. 1992;22(5):375–384.
   Google Scholar
• Chien S-C, Ou S-M, Shih C-J, et al. Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in terms of major cardiovascular disease outcomes in elderly patients: a nationwide population-based cohort study. Medicine (Baltimore). 2015;94(43):e1751.
   Google Scholar
• The ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547–1559.
   Google Scholar
• Ma C, Cao J, Lu X-C, et al. Cardiovascular and cerebrovascular outcomes in elderly hypertensive patients treated with either ARB or ACEI. JGC. 2012;9(3):252–257.
   Google Scholar
• Perry CM. Azilsartan medoxomil: a review of its use in hypertension. Clin Drug Investig. 2012;32(9):621–639.
   Google Scholar
• Jones JD, Jackson SH, Agboton C, et al. Azilsartan medoxomil (Edarbi): the eighth angiotensin II receptor blocker. Pharm Ther. 2011;36(10):634–640.
   Google Scholar
• Wilke RA, Berg RL, Vidaillet HJ, et al. Impact of age, CYP2C9 genotype and concomitant medication on the rate of rise for prothrombin time during the first 30 days of Warfarin therapy. Clin Med Res. 2005;3(4):207–213.
   Google Scholar
• Sica DA, Gehr TWB, Ghosh S. Clinical pharmacokinetics of Losartan. Clin Pharmacokinet. 2005;44(8):797–814.
   Google Scholar
• Marino MR, Vachharajani NN. Pharmacokinetics of irbesartan are not altered in special populations. J Cardiovasc Pharmacol. 2002;40(1):112–122.
   Google Scholar
• Nakashima M, Umemura K. The clinical pharmacology of losartan in Japanese subjects and patients. Blood Press Suppl. 1996;2:62–66.
   Google Scholar
• Goa KL, Wagstaff AJ. Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. Drugs. 1996;51(5):820–845.
   Google Scholar
• De Rosa ML, Cardace P, Rossi M, et al. Evaluation of long-term efficacy and tolerability of irbesartan in elderly hypertensive patients with renal impairment in an open-label study. Curr Ther Res. 2002;63(3):201–215.
   Google Scholar
• Siddiqui N, Husain A, Chaudhry L, et al. Pharmacological and pharmaceutical profile of valsartan. Rev. 2011;01(4):14–19.
   Google Scholar
• Martin J, Krum H. Role of valsartan and other angiotensin receptor blocking agents in the management of cardiovascular disease. Pharmacol Res. 2002;46(3):203–212.
   Google Scholar
• Sioufi A, Marfil F, Jaouen A, et al. The effect of age on the pharmacokinetics of valsartan. Biopharm Drug Dispos. 1998;19(4):237–244.
   Google Scholar
• Critchley JAJH, Gilchrist N, Ikeda L, et al. A randomized, double-masked comparison of the antihypertensive efficacy and safety of combination therapy with losartan and hydrochlorothiazide versus captopril and hydrochlorothiazide in elderly and younger patients. Curr Ther Res. 1996;57(5):392–407.
   Google Scholar
• Simpson KL, McClellan KJ. Losartan: a review of its use, with special focus on elderly patients. Drugs Aging. 2000;16(3):227–250.
   Google Scholar
• Weir MR. Renal effects of nonselective NSAIDs and coxibs. Cleve Clin J Med. 2002;69(Suppl 1):SI53–58.
   Google Scholar
• Loboz KK, Shenfield GM. Drug combinations and impaired renal function – the ‘triple whammy’. Br J Clin Pharmacol. 2005;59(2):239–243.
   Google Scholar
• European Society of Cardiology. ESH/ESC guidelines for the management of arterial hypertension. Eur Heart J. 2013;34:2159–2219.
   Google Scholar
• Dall JL. Guidelines for rational diuretic use in the elderly. Drugs. 1986;31(Suppl 4):202–206.
   Google Scholar
• Rodenburg EM, Hoorn EJ, Ruiter R, et al. Thiazide-associated hyponatremia: a population-based study. Am J Kidney Dis. 2013;62(1):67–72.
   Google Scholar
• Tu K, Campbell NR, Chen Z, et al. Use of beta-blockers for uncomplicated hypertension in the elderly: a cause for concern. J Hum Hypertens. 2007;21(4):271–275.
   Google Scholar
• Pilgrim A, Robinson S, Sayer AA, et al. An overview of appetite decline in older people. Nurs Older People. 2015;27(5):29–35.
   Google Scholar
• Diaconu CC, Balaceanu A, Bartos D. Diuretics, first-line antihypertensive agents: are they always safe in the elderly? Rom J Intern Med. 2014;52(2):87–90.
   Google Scholar
• Ellison DH, Loffing J. Thiazide effects and side effects: insights from molecular genetics. Hypertension. 2009;54(2):196–202.
   Google Scholar
• Beermann B, Groschinsky-Grind M. Clinical pharmacokinetics of diuretics. Clin Pharmacokinet. 1980;5(3):221–245.
   Google Scholar
• Van Wart SA, Shoaf SE, Mallikaarjun S, et al. Population-based meta-analysis of hydrochlorothiazide pharmacokinetics. Biopharm Drug Dispos. 2013;34(9):527–539.
   Google Scholar
• Brater DC. Diuretic therapy. N Engl J Med. 1998;339(6):387–395.
   Google Scholar
• Niemeyer C, Hasenfuss G, Wais U, et al. Pharmacokinetics of hydrochlorothiazide in relation to renal function. Eur J Clin Pharmacol. 1983;24(5):661–665.
   Google Scholar
• Liamis G, Filippatos TD, Elisaf MS. Thiazide-associated hyponatremia in the elderly: what the clinician needs to know. J Geriatr Cardiol. 2016;13(2):175–182.
   Google Scholar
• Shiga Y, Miura S, Morii J, et al. Comparison of the efficacy and safety of single-pill fixed-dose combinations of losartan/hydrochlorothiazide and valsartan/hydrochlorothiazide in patients with hypertension (SALT-VAT study). Intern Med. 2011;50(21):2477–2483.
   Google Scholar
• Schumann S-A HJ. When not to use beta-blockers in seniors with hypertension. J Fam Pract. 2008;57(1):18–21.
   Google Scholar
• Vogele A, Johansson T, Renom-Guiteras A, et al. Effectiveness and safety of beta blockers in the management of hypertension in older adults: a systematic review to help reduce inappropriate prescribing. BMC Geriatr. 2017;17(Suppl 1):224.
   Google Scholar
• Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387(10022):957–967.
   Google Scholar
• Ham AC, van Dijk SC, Swart KMA, et al. Beta-blocker use and fall risk in older individuals: original results from two studies with meta-analysis. Br J Clin Pharmacol. 2017;83(10):2292–2302.
   Google Scholar
• Jankovic SM. Pharmacokinetics of selective beta1-adrenergic blocking agents: prescribing implications. Expert Opin Drug Metab Toxicol. 2014;10(9):1221–1229.
   Google Scholar
• Gugler R, Allgayer H. Effects of antacids on the clinical pharmacokinetics of drugs. An Update. Clin Pharmacokinet. 1990;18(3):210–219.
   Google Scholar
• Fukao M, Ishida K, Horie A, et al. Variability of bioavailability and intestinal absorption mechanisms of metoprolol. Drug Metab Pharmacokinet. 2014;29(2):162–167.
   Google Scholar
• Goldner JA. Metoprolol-induced visual hallucinations: a case series. J Med Case Rep. 2012;6:65.
   Google Scholar
• McAinsh J, Cruickshank JM. Beta-blockers and central nervous system side effects. Pharmacol Ther. 1990;46(2):163–197.
   Google Scholar
• Bijl MJ, Visser LE, van Schaik RH, et al. Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users. Clin Pharmacol Ther. 2009;85(1):45–50.
   Google Scholar
• Opdam FL, Modak AS, Mooijaart SP, et al. CYP2D6 metabolism in frail elderly compared to non-frail elderly: a pilot feasibility study. Drugs Aging. 2015;32:1019–1027.
   Google Scholar
• Fleet JL, Weir MA, McArthur E, et al. Kidney function and population-based outcomes of initiating oral atenolol versus metoprolol tartrate in older adults. Am J Kidney Dis. 2014;64(6):883–891.
   Google Scholar
• Quarterman CP, Kendall MJ, Jack DB. The effect of age on the pharmacokinetics of metoprolol and its metabolites. Br J Clin Pharmacol. 1981;11(3):287–294.
   Google Scholar
• Grevel J, Thomas P, Whiting B. Population pharmacokinetic analysis of bisoprolol. Clin Pharmacokinet. 1989;17(1):53–63.
   Google Scholar
• Roux A, Henry JF, Fouache Y, et al. A pharmacokinetic study of acebutolol in aged subjects as compared to young subjects. Gerontology. 1983;29(3):202–208.
   Google Scholar
• Moyer TP, Sheps SG. Antihypertensive agents: role of therapeutic drug monitoring. Ther Drug Monit. 1981;3(3):217–230.
   Google Scholar
• Choi Y, Lee S, Cho SM, et al. Comparisons of the pharmacokinetics and tolerability of fixed-dose combinations of amlodipine besylate/losartan and amlodipine camsylate/losartan in healthy subjects: a randomized, open-label, single-dose, two-period, two-sequence crossover study. Drug Des Devel Ther. 2016;10:3021–3028.
   Google Scholar
• Hosie J, Meredith P. The pharmacokinetics of ramipril in a group of ten elderly patients with essential hypertension. J Cardiovasc Pharmacol. 1991;18(Suppl 2):S125–127.
   Google Scholar
• Macdonald NJ, Sioufi A, Howie CA, et al. The effects of age on the pharmacokinetics and pharmacodynamics of single oral doses of benazepril and enalapril. Br J Clin Pharmacol. 1993;36(3):205–209.
   Google Scholar
• Oberbauer R, Krivanek P, Turnheim K. Pharmacokinetics and pharmacodynamics of the diuretic bumetanide in the elderly. Clin Pharmacol Ther. 1995;57(1):42–51.
   Google Scholar
• Chow CK, Thakkar J, Bennett A, et al. Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic review. Lancet. 2017;389(10073):1035–1042.
   Google Scholar
• Webster R, Salam A, de Silva HA, et al. Fixed low-dose triple combination antihypertensive medication vs usual care for blood pressure control in patients with mild to moderate hypertension in Sri Lanka: a randomized clinical trial. JAMA. 2018;320(6):566–579.
   Google Scholar
• van Riet-Nales DA, Doeve ME, Nicia AE, et al. The accuracy, precision and sustainability of different techniques for tablet subdivision: breaking by hand and the use of tablet splitters or a kitchen knife. Int J Pharm. 2014;466(1):44–51.
   Google Scholar
• Notenboom K, Beers E, Riet-Nales Diana A, et al. Practical problems with medication use that older people experience: a qualitative study. J Am Geriatr Soc. 2014;62(12):2339–2344.
   Google Scholar
• Williams B, MacDonald TM, Morant S, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015 Nov 21;386(10008):2059–2068.
   Google Scholar
• Butler JV, McAvoy H, McEnroy D, et al. Spironolactone therapy in older patients–the impact of renal dysfunction. Arch Gerontol Geriatr. 2002 Jul–Aug;35(1):45–49.
   Google Scholar
• Officers A. Coordinators for the ACRGTA, lipid-lowering treatment to prevent heart attack T. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Jama. 2002 Dec 18;288(23):2981–2997.
   Google Scholar